🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. UI05MSP015CT

    United Therapeutics Europe Ltd

    Functional Dyspepsia

    phase 3 small molecule completed

    1 trial

  2. UT-15

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  3. UT-15C (treprostinil diolamine)

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    1 trial

  4. UT-15C SR

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    3 trials

  5. UT-15C SR

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  6. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo Nordisk A/S

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  7. UX007

    Ultragenyx UK Limited

    Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

    phase 3 small molecule terminated

    2 trials

  8. UX111

    ABEONA THERAPEUTICS INC.

    MPS IIIA

    phase 3 mab active

    1 trial

  9. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  10. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  11. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

    Alexion Europe SAS

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  12. Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Alexion Europe SAS

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  13. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)

    phase 3 small molecule active

    1 trial

  14. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial

  15. Upadacitinib Placebo, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial

  16. Upadacitinib, DUPILUMAB, Upadacitinib, Upadacitinib, Upadacitinib, Upadacitinib, DUPILUMAB

    AbbVie Deutschland GmbH & Co. KG

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  17. Upadacitinib, Placebo for upadacitinib tablet, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  18. Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  19. V114

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  20. V114

    Merck KGaA, Darmstadt, Germany

    Acute Otitis Media (AOM)

    phase 3 mab completed

    1 trial

  21. V181

    Merck KGaA, Darmstadt, Germany

    Healthy

    phase 3 mab active

    1 trial

  22. VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

  23. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  24. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources